The data should be submitted by August 12th 2021
Deal for 100 million doses with additional 100 million through 2023
Innovative solutions and a deep understanding of the market makes this a unique combination
Total income grew in the quarter
EPS climbs to Rs 9.25 for the quarter
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
AstraZeneca, Sinopharm and Moderna were part of the study
It is part of the company’s pain/analgesics portfolio of OTC products
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
Subscribe To Our Newsletter & Stay Updated
